I put your question to our AI as a test, and it gave a good answer (it relies on our extensive report and comments, so it’s not basic AI slop) 
Inderesin Nora AI
Aiforia Create is a central part of the company’s strategy, and it is specifically the “toolbox” that allows users to build AI models themselves without programming knowledge. Here is a summary of Create’s business model and potential based on Inderes’ analysis and the company’s releases:
1. What is Aiforia Create and where do the “thousands of models” come from?
Aiforia Create is a cloud-based platform where pathologists and researchers can annotate (mark) sample images and teach the AI to identify specific biomarkers or cell structures.
- Why thousands of models? This number reflects Create’s wide use, especially in preclinical research (universities, drug development). Researchers around the world are building very specific models for very narrow research topics (e.g., a specific protein in a mouse brain or malaria identification).
- Every new research question or biomarker often requires its own model. Therefore, the number grows rapidly, even though not all models end up in broad clinical use.
2. Business Model: SaaS + Volume
Aiforia’s business model is based on recurring billing, which typically consists of two parts:
- Platform License (SaaS): The customer pays for the right to use Create or other solutions (fixed annual fee).
- Usage-based fee (Volume): The revenue stream is tied to the number of samples analyzed.
3. “3rd party ecosystem” and clinical potential
You were right: there is a strong ecosystem element in Create.
- LDT (Laboratory Developed Test): Clinical laboratories (like the Italian La Fontana yesterday) can use Create to develop their own AI models and validate them for their own clinical use (so-called LDT tests).
- Potential: Aiforia does not need to develop and seek expensive regulatory approvals (such as CE-IVD or FDA) for every possible indication itself. Create provides tools to partners who do the work locally. Aiforia receives scalable income from this via platform usage and sample volumes.
- Strategic Role: While Aiforia has its own ready-made “Clinical Solutions” models (e.g., for breast and prostate cancer), Create allows the company’s platform to spread into laboratory workflows even through diagnostic needs for which there is no ready commercial product yet.
4. Italian laboratory example (La Fontana)
Yesterday’s release about the Italian laboratory is a good example of this:
- Even a small laboratory can use Create to “digitize” and AI-assist its own diagnostic process (in this case, cervical cancer screening).
- Although an individual contract is, according to Inderes’ estimate, moderate in size, it is an important opening in the Italian market and demonstrates how Create enables the expansion of clinical use.
Summary: Create’s potential lies in making Aiforia the “Windows of AI” for pathologists – a platform on which others build their applications, and Aiforia collects revenue based on the utilization rate.
Sources: Inderes’ extensive report 2025 and analyst comment April 24, 2026.
In addition to this, Aiforia can also take a model developed by its customer into its own product portfolio and gain benefits for the entire customer base:
Licensing a model developed by a partner (Case Mayo Clinic)
Mayo Clinic is Aiforia’s strategic partner, and they have used Aiforia Create to develop their own AI models.
- How does it work? Mayo Clinic developed and validated a colorectal cancer prognosis model (CRC) that can predict the risk of cancer recurrence based on sample images.
- Commercialization: Mayo Clinic has licensed this model it developed to Aiforia. This means that Aiforia can now sell this world-class expertise developed by Mayo Clinic to its other customers around the world as part of its “Clinical Solutions” range.
- Benefit: Aiforia gets a finished product with a world-class brand for sale, and Mayo Clinic likely receives royalty payments fro